Sabrina M Bedell1, Chloe Hedberg2, Anna Griffin3, Hannah Pearson4, Annelise Wilhite5, Nathan Rubin6, Britt K Erickson7. 1. University of Minnesota School of Medicine, Department of Obstetrics, Gynecology and Women's Health, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA. Electronic address: bedel017@umn.edu. 2. University of Minnesota School of Medicine, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA. Electronic address: hedb0079@umn.edu. 3. University of Minnesota School of Medicine, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA. Electronic address: griff618@umn.edu. 4. University of Minnesota School of Medicine, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA. Electronic address: pears871@umn.edu. 5. University of Minnesota School of Medicine, Department of Obstetrics, Gynecology and Women's Health, 420 Delaware St. SE, MMC 395, Minneapolis, MN 55455, USA. Electronic address: awilhite@umn.edu. 6. University of Minnesota School of Medicine, Division of Biostatistics, University of Minnesota School of Public Health, 420 Delaware St. SE, MMC 303, Minneapolis, MN 55455, USA. Electronic address: rubi0169@umn.edu. 7. University of Minnesota School of Medicine, Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, 420 Delaware St. SE, MMC 395 8395C, Minneapolis, MN 55455, USA. Electronic address: bkeric@umn.edu.
Abstract
OBJECTIVES: This study aims to evaluate whether re-excision or adjuvant radiation for stage I vulvar squamous cell carcinoma (SCC) with either a close or positive surgical margin improves recurrence-free survival. METHODS: Patients with pathologically confirmed FIGO stage I vulvar SCC who underwent primary surgical management between January 1, 1995 and September 30, 2017 and had positive or close (<8 mm) surgical margins were included. Kaplan-Meier curves were generated and compared using the log-rank test. RESULTS: Of 150 patients with stage I vulvar SCC, 47 (31.3%) had positive or close margins. Median follow-up time was 25 months (IQR 13-59 months). Twenty-one (44.6%) patients received additional treatment with re-excision (n = 17) or vulvar radiation (n = 4); 26 (55.3%) patients received no additional therapy. Patients with positive margins were more likely to receive additional therapy compared to patients with close margins (80% vs 35.1%, p = 0.03). The 2-year recurrence rates were similar between the no further therapy and the re-excision/vulvar radiation groups (11.5% vs 4.8%, p = 0.62). Local recurrence-free survival (RFS) and overall survival (OS) were similar between patients who received re-excision/vulvar radiation and patients who received no further therapy (p = 0.10 and p = 0.16, respectively). Subgroup analysis of the 37 patients with close margins demonstrated no difference in RFS or OS when patients received re-excision or adjuvant vulvar radiation compared to no additional therapy (p = 0.74 and p = 0.82, respectively). CONCLUSIONS: In our study, any additional treatment following primary surgical resection did not improve RFS or OS in stage IA and IB vulvar SCC. Larger studies are warranted in order to definitively determine the role of re-excision and adjuvant radiation in early stage disease.
OBJECTIVES: This study aims to evaluate whether re-excision or adjuvant radiation for stage I vulvar squamous cell carcinoma (SCC) with either a close or positive surgical margin improves recurrence-free survival. METHODS:Patients with pathologically confirmed FIGO stage I vulvar SCC who underwent primary surgical management between January 1, 1995 and September 30, 2017 and had positive or close (<8 mm) surgical margins were included. Kaplan-Meier curves were generated and compared using the log-rank test. RESULTS: Of 150 patients with stage I vulvar SCC, 47 (31.3%) had positive or close margins. Median follow-up time was 25 months (IQR 13-59 months). Twenty-one (44.6%) patients received additional treatment with re-excision (n = 17) or vulvar radiation (n = 4); 26 (55.3%) patients received no additional therapy. Patients with positive margins were more likely to receive additional therapy compared to patients with close margins (80% vs 35.1%, p = 0.03). The 2-year recurrence rates were similar between the no further therapy and the re-excision/vulvar radiation groups (11.5% vs 4.8%, p = 0.62). Local recurrence-free survival (RFS) and overall survival (OS) were similar between patients who received re-excision/vulvar radiation and patients who received no further therapy (p = 0.10 and p = 0.16, respectively). Subgroup analysis of the 37 patients with close margins demonstrated no difference in RFS or OS when patients received re-excision or adjuvant vulvar radiation compared to no additional therapy (p = 0.74 and p = 0.82, respectively). CONCLUSIONS: In our study, any additional treatment following primary surgical resection did not improve RFS or OS in stage IA and IB vulvar SCC. Larger studies are warranted in order to definitively determine the role of re-excision and adjuvant radiation in early stage disease.
Authors: David H Moore; Shamshad Ali; Wui-Jin Koh; Helen Michael; Mack N Barnes; Carolyn K McCourt; Howard D Homesley; Joan L Walker Journal: Gynecol Oncol Date: 2011-11-09 Impact factor: 5.482
Authors: Akila N Viswanathan; Alvaro P Pinto; Delray Schultz; Ross Berkowitz; Christopher P Crum Journal: Gynecol Oncol Date: 2013-06-05 Impact factor: 5.482
Authors: T Maggino; F Landoni; E Sartori; P Zola; A Gadducci; C Alessi; M Soldà; S Coscio; G Spinetti; A Maneo; A Ferrero; G Konishi De Toffoli Journal: Cancer Date: 2000-07-01 Impact factor: 6.860
Authors: Sarah Nicholas; Linda Chen; Amanda Choflet; Amanda Fader; Zachary Guss; Sarah Hazell; Daniel Y Song; Phuoc T Tran; Akila N Viswanathan Journal: Semin Radiat Oncol Date: 2017-10 Impact factor: 5.934
Authors: G Baiocchi; H Mantoan; L de Brot; L Badiglian-Filho; L Y Kumagai; C C Faloppa; A A B A da Costa Journal: Eur J Surg Oncol Date: 2015-10-22 Impact factor: 4.424
Authors: Noortje Pleunis; Maria E J Leermakers; Anneke A van der Wurff; Paul J J M Klinkhamer; Nicole P M Ezendam; Dorry Boll; Joanne A de Hullu; Johanna M A Pijnenborg Journal: Eur J Surg Oncol Date: 2018-06-06 Impact factor: 4.424